Return to Listing

4 result(s) for Ovary

PI Name Protocol # Title
Tanja Pejovic STUDY00015737 (ONC-DPX-Survivac-06): A Phase 1b Study of an Immunotherapeutic Vaccine, DPX-Survivac with Low Dose Cyclophosphamide and Epacadostat (INCB024360) in Patients with Recurrent Ovarian Cancer
Koenraad De Geest STUDY00016660 (OX4325) FOCUS: A Multicenter, Multinational, Double-Blind, 2-Arm, Randomized, Phase 2/3, Study of Physician's Choice Chemotherapy ([PCC] Weekly Paclitaxel or Pegylated Liposomal Doxorubicin [PLD]) Plus Bevacizumab and CA4P Versus PCC Plus Bevacizumab and Placebo for Subjects with Platinum-Resistant, Recurrent Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancer
Melissa Moffitt STUDY00016998 (APR-407) PiSARRO: p53 Suppressor Activation in Recurrent High Grade Serous Ovarian Cancer, a Phase Ib/II Study of Systemic Carboplatin/Pegylated Liposomal Doxorubicin (PLD) Combination Chemotherapy With or Without APR-246
Jackilen Shannon STUDY00017573 Focus Groups for Widespread Testing for Cancer Risk Syndromes
 

You may also qualify for Phase 1 Program trials.

 
For more information:
Email: trials@ohsu.edu
Call: 503-494-1080